The macrophage mannose receptor plays an important role in both host defense and in regulation of inflammation. Physiologic ligands for this receptor are both particulate and soluble, and include pathogens such as Pseudomonas, Candida, and Pneumocystis; and, proteins such as neutrophil- derived myeloperoxidase and extracellular lysosomal hydrolases. The receptor binds these ligands and delivers them tot he phagolysosomal compartment for degradation, thus removing agents for the extracellular space that might contribute to injury or continuing inflammation. The mannose receptor is exquisitely regulated by modulating agents that are produced at or travel to the site of injury. The receptor is inactivated or down-regulated by proteases, oxidants, endotoxin, and interferon- gamma. Alternatively, the mannose receptor is dramatically up-regulated by anti-inflammatory agents such as dexamethasone. The receptor is not present on circulating monocytes, but appears during in vitro differentiation induced by M-CSF. The overall goal of this project is to study potential mechanisms of regulation of the mannose receptor in in vivo lung injury models.
The specific aims of this project are 1) to characterize the regulation of the macrophage mannose receptor in the endotoxin-treated rat and sheep models of acute lung injury, and in human alveolar macrophages isolated from patients with ARDS; 2) to determine the potential role of xanthine oxidase-derived oxidants and macrophage-derived nitric oxide in the down- regulation of the mannose receptor; and, 3) to study the effect of immunosuppressive or antiinflammatory agents on the regulation of the mannose receptor, xanthine oxidase, and nitric oxide synthase in in vitro and in vivo models.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center (P50)
Project #
5P50HL019153-22
Application #
6109483
Study Section
Project Start
1997-12-01
Project End
1999-06-30
Budget Start
Budget End
Support Year
22
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Brigham, K L; Lane, K B; Meyrick, B et al. (2000) Transfection of nasal mucosa with a normal alpha1-antitrypsin gene in alpha1-antitrypsin-deficient subjects: comparison with protein therapy. Hum Gene Ther 11:1023-32
Conner, B D; Bernard, G R (2000) Acute respiratory distress syndrome. Potential pharmacologic interventions. Clin Chest Med 21:563-87
Mangialardi, R J; Martin, G S; Bernard, G R et al. (2000) Hypoproteinemia predicts acute respiratory distress syndrome development, weight gain, and death in patients with sepsis. Ibuprofen in Sepsis Study Group. Crit Care Med 28:3137-45
Brigham, K L; Stecenko, A A (2000) Gene therapy for acute lung injury. Intensive Care Med 26 Suppl 1:S119-23
Arons, M M; Wheeler, A P; Bernard, G R et al. (1999) Effects of ibuprofen on the physiology and survival of hypothermic sepsis. Ibuprofen in Sepsis Study Group. Crit Care Med 27:699-707
Peters, M T; Brigham, K L; King, G A et al. (1999) Optimization of cationic liposome-mediated gene transfer to human bronchial epithelial cells expressing wild-type or abnormal cystic fibrosis transmembrane conductance regulator (CFTR). Exp Lung Res 25:183-97
Wheeler, A P; Bernard, G R (1999) Treating patients with severe sepsis. N Engl J Med 340:207-14
Snapper, J R; Trochtenberg, D S; Hwang, Y S et al. (1999) Effect of pulmonary edema on tracheal diameter. Respiration 66:522-7
Dupont, W D; Plummer Jr, W D (1998) Power and sample size calculations for studies involving linear regression. Control Clin Trials 19:589-601
Clark, M P; Chow, C W; Rinaldo, J E et al. (1998) Multiple domains for initiator binding proteins TFII-I and YY-1 are present in the initiator and upstream regions of the rat XDH/XO TATA-less promoter. Nucleic Acids Res 26:2813-20

Showing the most recent 10 out of 202 publications